

Allopurinol in Functional Impairment (ALFIE) trial: improving muscle strength

Submission date 07/03/2012	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 17/04/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 28/05/2020	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Muscle weakness that occurs as we get older can lead to a gradual slowing down of activity and increased difficulty in functioning independently. It may also lead to an increased risk of falls and can have a significant impact on social and healthcare costs. Exercise has been shown to improve muscle strength but many older people are unable to exercise due to underlying health problems so research into alternative treatments to improve muscle weakness are needed. There is now strong and compelling reasons from recent experimental studies both in animals and humans to show that an established drug used to treat gout called allopurinol may also have beneficial effects on muscles. It does this by reducing harmful molecules in muscle called free radicals that reduce the ability of the muscle to make use of oxygen and therefore make them tire more easily. Allopurinol has also been shown to improve blood flow to the muscles, again improving oxygen availability in them, and makes muscles more elastic so they are more efficient. This study will examine the effects of allopurinol compared to a placebo (dummy) medicine on how well muscles function in older people and is designed to show if a 20-week course of allopurinol improves how well leg muscles work.

Who can participate?

People aged 65 and over who are unable to walk more than 400 m in 6 minutes.

What does the study involve?

The participants will undergo a full clinical examination and routine screening blood tests during the first (screening) visit. They will then be randomly assigned to take either allopurinol 300 mg twice a day or placebo (dummy) tablets twice a day for 20 weeks. There will be two monitoring visits and blood tests during that time just to make sure the participants are tolerating their medications without any difficulty.

What are the possible benefits and risks of participating?

There are no direct benefits to the patients participating as allopurinol is not currently licensed for this particular condition. If the results are positive, it may help future patients with sarcopenia. Just like any drug, some people may have an adverse reaction to allopurinol but

these are usually mild (rash, gastrointestinal upset). We will be monitoring patients during the trial and provide them with contact telephone numbers if they feel unwell on the trial medication.

Where is the study run from?

The study will be run from the University of Dundee Medical School (UK).

When is study starting and how long is it expected to run for?

The study ran from October 2012 to September 2014.

Who is funding the study?

Dunhill Medical Trust (UK).

Who is the main contact?

Dr Jacob George

j.george@dundee.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Jacob George

Contact details

University of Dundee

Department of Clinical Pharmacology

Medical Research Institute

Ninewells Hospital and Medical School

Dundee

United Kingdom

DD1 9SY

-

j.george@dundee.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2014-004122-18

ClinicalTrials.gov (NCT)

NCT01550107

Protocol serial number

GEO006

Study information

Scientific Title

A prospective study to evaluate the effect of allopurinol on muscle energetics in primary sarcopenia

Acronym

ALFIE

Study objectives

Sarcopenia is increasingly becoming a significant cause of frailty, loss of independence and physical disability in ageing western populations. Recent experimental evidence has revealed that skeletal muscle is particularly susceptible to oxidative stress and that oxidative stress plays a prominent role in the development and progression of sarcopenia. Our group have previously shown that the xanthine oxidase inhibitor allopurinol is able to abolish vascular oxidative stress and improve endothelial function in cohorts such as optimally treated chronic heart failure and chronic kidney disease. Recently, our group has also shown that allopurinol improves exercise tolerance and time to ST-depression in optimally treated coronary artery disease, suggesting that allopurinol could also exert its effects through ATP and/or oxygen sparing mechanisms.

Therefore, we propose a randomised double blind placebo-controlled parallel group trial of allopurinol in patients with primary sarcopenia using MR-spectroscopy and Flow Mediated Dilatation to investigate the possible mechanisms that underlie this possibility.

On 11/11/2014 the following changes were made to the trial record:

1. The public title was changed from 'Allopurinol in sarcopenia' to 'Allopurinol in Functional Impairment (ALFIE) trial: improving muscle strength'.
2. The acronym 'ALFIE' was added.
3. The target number of participants was changed from 70 to 124.
4. Dunhill Medical Trust (UK) was added to the sources of funding field.
5. The anticipated start date was changed from 01/10/2012 to 01/12/2014.
6. The anticipated end date was changed from 30/09/2014 to 30/11/2016 .

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Prospective randomised double blind placebo controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Primary Sarcopenia

Interventions

Allopurinol vs Placebo

Following a screening visit, participants will be randomised to either allopurinol 300mg twice daily or placebo twice daily in a randomised double blind fashion.

They will undergo screening blood tests, baseline non-invasive vascular function assessments and MR-spectroscopy. Following this they will attend two monitoring visits every 8 weeks. The total involvement per participant is 20 weeks. At the end of the study the participants, will undergo final blood tests, baseline non-invasive vascular function assessments and MR-spectroscopy. Transport will be provided for participants within Tayside.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Improvement in muscle energetics as measured by magnetic resonance (MR) spectroscopy

Key secondary outcome(s)

1. Change in muscle volume (as measured by cross-sectional area on MR obtained during perfusion mapping)
2. Short Performance Battery test
3. Change in Flow Mediated Dilatation
4. Markers of oxidative stress (F2-Isoprostanes)

Added 11/11/2014:

5. Six-Minute Walk test
6. Quality of Life measured by EuroQOL EQ5D questionnaire

Completion date

28/02/2018

Eligibility

Key inclusion criteria

Current inclusion criteria as of 11/11/2014:

1. Age 65 years and over
2. 6-Minute Walk Distance <400 m

Previous inclusion criteria:

1. Age 65 and over
2. Muscle strength (grip strength <20kg women;<30kg men) AND physical performance (Short Physical Performance Battery test score less than or equal to 8/12). This will ensure both that the study population have sarcopenia according to European consensus guidelines
3. Gait speed less than 0.8m/s

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

All

Total final enrolment

124

Key exclusion criteria

Current exclusion criteria as of 11/11/2014:

1. Documented history of peripheral arterial disease
2. Pre-existing diagnosis of severe heart failure (LVEF <35%)
3. Malignancy under active treatment (excluding basal cell carcinoma)
4. Severe COPD (physician diagnosis)
5. Intolerance to allopurinol
6. Individuals with Active Acute Gout currently taking allopurinol; or those who have stopped taking allopurinol ≤ 1 month previously for this condition.
7. On long-term high-dose steroids (eq. Prednisolone >10 mg/day due to risk of steroid-induced myopathy and osteoporosis)
8. Immobility that would render the patient incapable of doing the Short Physical Performance Battery Test (SPPB) or 6MWT
9. Patients who have participated in any other clinical drug trial within the previous 30 days will be excluded
10. Cognitive impairment precluding informed consent
11. Any other considered by a study physician to be inappropriate for inclusion

Previous exclusion criteria:

1. Previously enrolled into the study
2. Pre-existing diagnosis of heart failure or any malignancy (excluding basal cell carcinoma)
3. Documented intolerance to allopurinol
4. Immobility that would render the patient incapable of doing the Short performance Battery Test (SPBT)

Date of first enrolment

26/02/2015

Date of final enrolment

22/02/2017

Locations**Countries of recruitment**

United Kingdom

Scotland

Study participating centre

University of Dundee
Dundee
United Kingdom
DD1 9SY

Sponsor information

Organisation

University of Dundee (UK)

ROR

<https://ror.org/03h2bxq36>

Funder(s)

Funder type

Charity

Funder Name

Dunhill Medical Trust (UK)

Alternative Name(s)

The Dunhill Medical Trust, Dunhill Medical Trust, DunhillMedical, DMT

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[Basic results](#)

28/05/2020 No

No

[Participant information sheet](#)

Participant information sheet

11/11/2025

11/11/2025 No

Yes